On the opposite side, these considerations would allow to suppose that tumor-associated inhibition of HIPK2 activity might strongly contribute to chemoresistance and tumor progression, in addition to other better-characterized events, such as p53 mutation/inactivation and MDM2 or ΔNp63α overexpression. The gene discussed is MDM2; the disease is neoplasm.